4.7 Review

Immunomodulation by mesenchymal stem cells and clinical experience

Journal

JOURNAL OF INTERNAL MEDICINE
Volume 262, Issue 5, Pages 509-525

Publisher

WILEY
DOI: 10.1111/j.1365-2796.2007.01844.x

Keywords

acute graft-versus-host disease; haematopoietic; stem cell transplantation; immunomodulation; mesenchymal stem cells; tissue toxicity

Ask authors/readers for more resources

Mesenchymal stem cells (MSCs) from adult marrow can differentiate in vitro and in vivo into various cell types, such as bone, fat and cartilage. MSCs preferentially home to damaged tissue and may have therapeutic potential. In vitro data suggest that MSCs have low inherent immunogenicity as they induce little, if any, proliferation of allogeneic lymphocytes. Instead, MSCs appear to be immunosuppressive in vitro. They inhibit T-cell proliferation to alloantigens and mitogens and prevent the development of cytotoxic T-cells. In vivo, MSCs prolong skin allograft survival and have several immunomodulatory effects, which are presented and discussed in the present study. Possible clinical applications include therapy-resistant severe acute graft-versus-host disease, tissue repair, treatment of rejection of organ allografts and autoimmune disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available